載入...
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years with Non-Valvular Atrial Fibrillation
Dabigatran has been shown to be superior to warfarin for stroke prevention in non-valvular atrial fibrillation (NVAF) but with higher out-of-pocket costs for patients. Although dabigatran has been shown to be cost-effective from a societal perspective, cost implications for individual patients and i...
Na minha lista:
| 發表在: | J Med Econ |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4627374/ https://ncbi.nlm.nih.gov/pubmed/23621506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3111/13696998.2013.800523 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|